SCHEMBL4588458

SCHEMBL4588458

O=C1O[C@H](COCc2ccccc2)[C@@H](F)[C@H](OCc2ccccc2)[C@H]1OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 2/20 0.50
ACHE P22303 2/20 0.50
LMNA P02545 1/20 0.41
TACR2 P21452 3/20 0.39
HTR1A P08908 1/20 0.39
PDE2A O00408 1/20 0.39
NT5E P21589 1/20 0.39
PDPK1 O15530 1/20 0.37
MTOR P42345 1/20 0.37
CTRB1 P17538 1/20 0.37
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
FASN P49327 1/20 0.36
PTPN1 P18031 3/20 0.36
CDC25B P30305 3/20 0.36
CA1 P00915 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31725358 0.91 BCHE (0.47) BCHEACHELMNATACR2HTR1A
SCHEMBL18852561 0.89 BCHE (0.54) BCHEACHELMNATACR2HTR1A
SCHEMBL22796970 0.89 BCHE (0.54) BCHEACHELMNATACR2HTR1A
SCHEMBL7522263 0.89 BCHE (0.54) BCHEACHELMNATACR2HTR1A
SCHEMBL3304205 0.89 BCHE (0.54) BCHEACHELMNATACR2HTR1A
SCHEMBL18497676 0.89 BCHE (0.54) BCHEACHELMNATACR2HTR1A
SCHEMBL30801101 0.89 BCHE (0.54) BCHEACHELMNATACR2HTR1A
SCHEMBL12896359 0.89 BCHE (0.54) BCHEACHELMNATACR2HTR1A
SCHEMBL14571363 0.89 BCHE (0.54) BCHEACHELMNATACR2HTR1A
SCHEMBL13591463 0.89 BCHE (0.54) BCHEACHELMNATACR2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11014917-B2 5-fluoro-c-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators JANSSEN PHARMACEUTICA NV (BE) 2021-05-25 US disclosed
US-11014917-B2 5-fluoro-c-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators JANSSEN PHARMACEUTICA NV (BE) 2021-05-25 US disclosed
US-20200291004-A1 5-FLUORO-C-(ARYL OR HETEROCYCLYL)-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-09-17 US disclosed
US-20200291004-A1 5-FLUORO-C-(ARYL OR HETEROCYCLYL)-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-09-17 US disclosed
US-10696662-B2 5-fluoro-C-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators JANSSEN PHARMACEUTICA NV (BE) 2020-06-30 US disclosed
US-10696662-B2 5-fluoro-C-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators JANSSEN PHARMACEUTICA NV (BE) 2020-06-30 US disclosed
US-20190055226-A1 5-FLUORO-C-(ARYL OR HETEROCYCLYL)-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-02-21 US disclosed
US-20190055226-A1 5-FLUORO-C-(ARYL OR HETEROCYCLYL)-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-02-21 US disclosed
US-20080027014-A1 Novel SGLT inhibitors TANABE SEIYAKU CO., LTD. 2008-01-31 US disclosed
US-20080027014-A1 Novel SGLT inhibitors TANABE SEIYAKU CO., LTD. 2008-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190055226-A1 5-FLUORO-C-(ARYL OR HETEROCYCLYL)-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS SLC5A2, SLC5A1, SLC2A2 BCHE 3330/4885ACHE 3917/4885LMNA 3723/4885
US-10696662-B2 5-fluoro-C-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators SLC5A2, SLC5A1, SLC2A2 BCHE 3330/4885ACHE 3917/4885LMNA 3723/4885
US-20200291004-A1 5-FLUORO-C-(ARYL OR HETEROCYCLYL)-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS SLC5A2, SLC5A1, SLC2A2 BCHE 3273/4885ACHE 3910/4885LMNA 3769/4885
US-20080027014-A1 Novel SGLT inhibitors SLC5A1, SLC5A2, SLC10A1 BCHE 4266/4885ACHE 4523/4885LMNA 3997/4885
US-11014917-B2 5-fluoro-c-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators SLC5A2, SLC5A1, SLC2A2 BCHE 3273/4885ACHE 3910/4885LMNA 3769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.